{"title":"Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem.","authors":"Nami Obara, Toshiaki Komatsu, Kazuyoshi Shiratsu, Yuto Akamada, Katsuya Otori","doi":"10.1080/1120009X.2025.2456327","DOIUrl":null,"url":null,"abstract":"<p><p>This retrospective study investigated whether piperacillin/tazobactam (PIPC/TAZ) monotherapy affects renal function compared to cefepime (CFPM) or meropenem (MEPM) monotherapy. Hospitalized patients who received PIPC/TAZ, CFPM, or MEPM monotherapy between April 2021 and December 2022 were enrolled in this study. We used inverse probability of treatment weighting (IPTW) to balance baseline characteristics and compare the incidence of acute kidney injury (AKI). Overall, 259, 104, and 98 patients were enrolled in the PIPC/TAZ, CFPM, and MEPM groups, respectively. After applying IPTW, PIPC/TAZ administration was found to be significantly associated with an increased risk of AKI (odds ratio [OR]: 6.75, 95% confidence interval [CI]: 1.30-34.8, <i>p</i> = 0.023 compared to CFPM; and OR: 7.71, 95% CI: 1.00-59.2, <i>p</i> = 0.049 compared to MEPM). PIPC/TAZ monotherapy may be associated with a higher risk of AKI than CFPM or MEPM monotherapy.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2456327","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
This retrospective study investigated whether piperacillin/tazobactam (PIPC/TAZ) monotherapy affects renal function compared to cefepime (CFPM) or meropenem (MEPM) monotherapy. Hospitalized patients who received PIPC/TAZ, CFPM, or MEPM monotherapy between April 2021 and December 2022 were enrolled in this study. We used inverse probability of treatment weighting (IPTW) to balance baseline characteristics and compare the incidence of acute kidney injury (AKI). Overall, 259, 104, and 98 patients were enrolled in the PIPC/TAZ, CFPM, and MEPM groups, respectively. After applying IPTW, PIPC/TAZ administration was found to be significantly associated with an increased risk of AKI (odds ratio [OR]: 6.75, 95% confidence interval [CI]: 1.30-34.8, p = 0.023 compared to CFPM; and OR: 7.71, 95% CI: 1.00-59.2, p = 0.049 compared to MEPM). PIPC/TAZ monotherapy may be associated with a higher risk of AKI than CFPM or MEPM monotherapy.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
